Bruker Corp. (BRKR) Sheds 8.6% on Dismal Earnings, Outlook

We recently published 10 Stocks Bleeding Early. Bruker Corporation (NASDAQ:BRKR) is one of the companies that stood stronger last week.

Bruker Corp. fell for a fifth straight day on Monday, dropping 8.62 percent to close at $34.72 apiece after posting a dismal earnings performance in the first half of the year and lowering its growth outlook for full-year 2025.

In a statement, Bruker Corporation (NASDAQ:BRKR) said both attributable net income and revenues in the second quarter of the year finished flat at $7.6 million and $800 million, respectively.

Looker_Studio/Shutterstock.com

Meanwhile, attributable net income for the first half declined by 57 percent to $25 million from $58.5 million year-on-year, while revenues were higher by 4 percent to $1.6 billion versus $1.52 billion in the same comparable period.

“Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets,” said Bruker Corporation (NASDAQ:BRKR) President and CEO Frank Laukien.

“Tariffs and a stiff currency headwind could not yet be compensated for by our mitigating price, supply chain, and cost actions in the second quarter,” he added.

For full-year 2025, Bruker Corporation (NASDAQ:BRKR) expects revenues to end at $3.43 billion to $3.5 billion, or a 2-4 percent growth from the $3.37 billion last year. The updated figures, however, were lower than the previous guidance of $3.48 billion to $3.55 billion.